Danaher Corp (DHR) FinancialsDHRFinancialDanaher Corp

Danaher Corporation (DHR) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Diagnostics, accounting for 39.4% of total sales, equivalent to $2.47B. Other significant revenue streams include Biotechnology and Life Sciences. Understanding this composition is critical for investors evaluating how DHR navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Danaher Corporation maintains a gross margin of 57.64%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 17.99%, while the net margin is 13.89%. These profitability ratios, combined with a Return on Equity (ROE) of 7.61%, provide a clear picture of how effectively DHR converts its operational activities into shareholder value.

In the context of the broader market, DHR competes directly with industry leaders such as ISRG and SYK. With a market capitalization of $142.32B, it holds a leading position in the sector. When comparing efficiency, DHR's gross margin of 57.64% stands against ISRG's 67.78% and SYK's 65.78%. Such benchmarking helps identify whether Danaher Corporation is trading at a premium or discount relative to its financial performance.

Danaher has shown consistent revenue growth, with Q2 2026 revenue at $6.265 billion and a gross margin of 57.64%. The net income for Q2 2026 was $870 million, reflecting strong profitability.